Arcutis Biotherapeutics (ARQT) Non-Current Debt (2021 - 2025)
Historic Non-Current Debt for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $107.5 million.
- Arcutis Biotherapeutics' Non-Current Debt rose 228.65% to $107.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $107.5 million, marking a year-over-year increase of 228.65%. This contributed to the annual value of $107.2 million for FY2024, which is 4687.63% down from last year.
- According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Non-Current Debt is $107.5 million, which was up 228.65% from $107.0 million recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' Non-Current Debt ranged from a high of $203.8 million in Q2 2024 and a low of $72.4 million during Q4 2021
- Moreover, its 5-year median value for Non-Current Debt was $152.2 million (2022), whereas its average is $147.2 million.
- As far as peak fluctuations go, Arcutis Biotherapeutics' Non-Current Debt soared by 17335.04% in 2022, and later tumbled by 4765.74% in 2024.
- Over the past 5 years, Arcutis Biotherapeutics' Non-Current Debt (Quarter) stood at $72.4 million in 2021, then soared by 173.35% to $197.8 million in 2022, then grew by 2.04% to $201.8 million in 2023, then tumbled by 46.88% to $107.2 million in 2024, then increased by 0.28% to $107.5 million in 2025.
- Its Non-Current Debt stands at $107.5 million for Q3 2025, versus $107.0 million for Q2 2025 and $107.6 million for Q1 2025.